1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited

GLAXO.NS
GlaxoSmithKline Pharmaceuticals LimitedIN flagNational Stock Exchange of India
2,402.20
INR
+6.70
- -
406.95BMarket Cap
GlaxoSmithKline Pharmaceuticals Limited
GLAXO.NS
(National Stock Exchange of India)

Recent

price

2,402.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
126.98
142.27
156.45
150.81
- -
158.45
171.69
165.64
182.92
188.84
171.15
192.68
190.45
203.17
219.95
224.76
220.78
Revenue per Share
33.09
25.3
33.17
28.43
- -
22.2
19.88
20.7
26.29
5.5
21.14
100.04
36.05
34.83
54.76
61.15
56.1
Basic EPS, GAAP
27.03
17.31
18.51
16.61
- -
8.2
13.83
27.91
24.17
19.6
31.5
45.81
25.98
32.51
74.68
50.06
- -
Free Cash Flow per Basic Share
14.94
19.93
22.32
24.87
- -
31.25
25
15
17.5
20
39.97
29.91
90.05
31.97
44.24
42.15
- -
Dividend per Share
5
72.27
73.03
69.03
186.13
77.67
67.25
70.23
80.29
61.68
42.82
112.21
57.9
61.74
72.49
91.64
- -
Book Value per Share
115.2
114.26
118.46
117.45
288.55
128.88
116.56
117.15
122.44
104.54
84.7
155.16
100.77
103.54
114.4
133.46
- -
Tangible Book Value per Share
169
169
169
169
85
169
169
169
169
169
169
169
169
169
169
169
169
Basic Weighted Avg Shares
21,511
24,102
26,504
25,548
- -
26,843
29,085
28,061
30,987
31,991
28,994
32,641
32,264
34,418
37,260
38,076
37,397
Sales/Revenue/Turnover
40.52
32.76
30.07
20.33
- -
17.21
13.5
16.98
17.96
18.36
17.92
21.41
23.2
24.36
29.91
32.77
30.27
Operating Margin (%)
176
204
178
199
- -
249
263
380
486
827
786
682
658
697
668
664
659
Depreciation Expense
5,606
4,286
5,619
4,817
- -
3,761
3,368
3,507
4,454
932
3,581
16,947
6,107
5,900
9,276
10,360
9,503
Net Income, GAAP
33.66
29.13
32.66
32.3
- -
34.97
34.11
35.05
34.76
69.52
36.72
51.12
27.35
27.72
26.38
26.32
26.31
Effective Tax Rate (%)
26.06
17.78
21.2
18.85
- -
14.01
11.58
12.5
14.37
2.91
12.35
51.92
18.93
17.14
24.89
27.21
25.41
Profit Margin (%)
16,646
17,455
18,103
17,350
20,742
15,888
9,524
5,816
5,551
7,506
8,481
20,096
11,679
12,735
15,047
18,280
- -
Working Capital
52
46
41
36
26
16
10
6
2
269
202
76
35
65
25
173
- -
LT Debt
19,516
19,357
20,068
19,897
24,441
21,832
20,069
20,573
21,398
18,206
14,783
26,630
17,413
17,776
19,513
22,674
- -
Total Equity
30.86
28.78
27.3
17.65
- -
12.97
12.4
14.77
16.23
8.36
17.95
14.8
21.75
29.41
36.05
34.7
- -
Return on Invested Capital (%)
622.86
65.01
45.5
39.9
- -
25.98
27.41
30.09
34.94
7.76
39.03
126.49
41.96
57.38
80.66
73.52
441.1
Return on Capital (%)
661.81
65.48
45.65
40.03
- -
26.01
27.44
30.12
34.93
7.75
40.46
129.06
42.38
58.22
81.59
74.52
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
75
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
25
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
169
- -
Market Capitalization
381,467
487,916
573,908

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
34,099
- -
Cash, Cash Equivalents & STI
- -
24,981
- -
Accounts Receivable, Net
- -
2,925
- -
Inventories
- -
4,817
- -
Total Current Liabilities
- -
19,052
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
75
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.83%
14.72%
16.2%
Free Cash Flow
32.29%
24.8%
-32.97%
Net Income, GAAP
60.06%
74.95%
11.69%
Sales/Revenue/Turnover
3.77%
5.71%
2.19%
Total Cash Common Dividend
21.59%
29.02%
-4.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,617
9,570
8,053
9,179
34,418
2025
8,146
10,108
9,494
9,744
37,260
2026
8,052
10,413
9,953
- -
38,076

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7.81
12.84
2.7
- -
34.83
2025
10.76
14.91
13.57
15.52
54.76
2026
12.1
17.45
16.4
- -
61.15

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
31.97
2025
- -
- -
- -
- -
44.24
2026
- -
- -
- -
- -
42.15
Similar Companies
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (600671.SS)
Otsuka Holdings Co., Ltd. (OTSKY)
Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ)
Grifols, S.A. (GIFLF)
Dechra Pharmaceuticals PLC (DPHAY)
Gilead Sciences, Inc. (GIS.DE)
Business
GlaxoSmithKline Pharmaceuticals Limited is a prominent healthcare enterprise focused on the research, development, production, and distribution of pharmaceutical remedies and immunizations, primarily within India. The company delivers a broad spectrum of prescription medications for various therapeutic needs including anti-infectives, respiratory conditions, dermatological issues, women's health, diabetes management, cardiovascular ailments, and rare diseases. Additionally, its portfolio encompasses a comprehensive array of vaccines. Products are offered under well-recognized brands such as Augmentin, Calpol, Ceftum, Eltroxin, Infanrix Hexa, Synflorix, Havrix, Menveo, Nucala, and Trelegy Ellipta. With a history dating back to its incorporation in 1924, the entity was initially known as H. J. Foster & Co. Limited and later SmithKline Beecham Pharmaceuticals India Ltd., before adopting its current name in 2001. Headquartered in Mumbai, India, GlaxoSmithKline Pharmaceuticals Limited maintains manufacturing operations in Nashik, Maharashtra, and continues to expand its offerings, including a recent foray into oncology in the Indian market.